Identification of Serum Biomarker Signatures Associated with Pancreatic Cancer

Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients wit...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2012-05, Vol.72 (10), p.2481-2490
Main Authors: WINGREN, Christer, SANDSTRÖM, Anna, SEGERSVÄRD, Ralf, CARLSSON, Anders, ANDERSSON, Roland, LÖHR, Matthias, BORREBAECK, Carl A. K
Format: Article
Language:English
Subjects:
80 and over
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Biological Markers/blood
Biological/blood
Biomarkers - blood
Biomarkers, Tumor - blood
Cancer and Oncology
Cancer och onkologi
Carcinoma
Carcinoma, Pancreatic Ductal - blood
Chronic/blood
Clinical Medicine
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Klinisk medicin
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical and Health Sciences
Medical sciences
Medicin och hälsovetenskap
Middle Aged
Pancreatic Ductal/blood
Pancreatic Neoplasms - blood
Pancreatitis
Pancreatitis - diagnosis
Pancreatitis, Chronic - blood
Pharmacology. Drug treatments
Tumor Markers
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients with pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N). Serum biomarker signatures were derived from training cohorts and the predictive power was evaluated using independent test cohorts. The results identified serum portraits distinguishing pancreatic cancer from N [receiver operating characteristics area under the curve (AUC) of 0.95], chronic pancreatitis (0.86), and AIP (0.99). Importantly, a 25-serum biomarker signature discriminating pancreatic cancer from the combined group of N, chronic pancreatitis, and AIP was determined. This signature exhibited a high diagnostic potential (AUC of 0.88). In summary, we present the first prevalidated, multiplexed serum biomarker signature for diagnosis of pancreatic cancer that may improve diagnosis and prevention in premalignant diseases and in screening of high-risk individuals.
ISSN:0008-5472
1538-7445
1538-7445
DOI:10.1158/0008-5472.CAN-11-2883